Safinamide prevents lipopolysaccharide (LPS)-induced inflammation in macrophages by suppressing TLR4/NF-κB signaling

LuLu Qian1, Jun-Zhao Li1, XueMei Sun1

  • 1Department of Pediatrics, Taizhou People's Hospital, Taizhou, Jiangsu 225300, China.

Insights

Safinamide, a Parkinson's disease drug, was found to reduce inflammatory responses in macrophages. It inhibited key inflammatory molecules and pathways, suggesting a potential protective role against inflammation.

Area of Science:

  • Immunology
  • Pharmacology
  • Cell Biology

Background:

  • Inflammation is a critical defense mechanism involving macrophages.
  • Uncontrolled inflammation can lead to tissue damage.
  • Safinamide is a known monoamine oxidase B (MAOB) inhibitor used for Parkinson's disease.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of safinamide on lipopolysaccharide (LPS)-activated macrophages.
  • To explore the molecular mechanisms underlying safinamide's action.

Main Methods:

  • Macrophages were treated with LPS and safinamide.
  • Expression of pro-inflammatory cytokines (IL-1α, TNF-α, IL-6) was measured.
  • Production of chemokines (CXCL1, CCL2), nitric oxide (NO), prostaglandin E2 (PGE2), and matrix metalloproteinases (MMPs) was assessed.
  • The role of the TLR4/NF-κB signaling pathway was investigated.

Main Results:

  • Safinamide significantly inhibited the expression of IL-1α, TNF-α, and IL-6.
  • Safinamide suppressed CXCL1 and CCL2 production, reducing leukocyte migration.
  • Safinamide decreased iNOS-derived NO, COX-2-derived PGE2, MMP-2, and MMP-9.
  • These effects were dependent on the inhibition of the TLR4/NF-κB pathway.

Conclusions:

  • Safinamide demonstrates potent anti-inflammatory properties in macrophages.
  • Safinamide modulates key inflammatory mediators and pathways.
  • Safinamide may offer a protective effect against inflammatory conditions.